What's Happening?
India is gearing up to produce generic versions of semaglutide, the active ingredient in Novo Nordisk's Ozempic, as the patent is set to expire in March. Indian pharmaceutical companies, including Dr. Reddy's Laboratories and Cipla, are preparing to manufacture
these weight-loss drugs, potentially reducing prices significantly. Analysts predict a price war in India, with costs dropping by up to 90%. This development could position India as a major supplier of affordable weight-loss medications, similar to its role in the global supply of HIV drugs.
Why It's Important?
The expiration of the semaglutide patent in India could lead to a significant reduction in the cost of weight-loss drugs, making them more accessible to a broader population. This move could also enhance India's position as a key player in the global pharmaceutical market, potentially impacting international drug pricing and availability. For the U.S., where the patent remains in effect until the 2030s, this development highlights the ongoing challenges of drug affordability and access, as well as the potential for future market shifts once the patent expires.
